Dr. Weijia Wang and colleagues conducted a clinical study involving 12 patients with SLE and LN who underwent bi-specific BCMA-CD19 compound CAR-T (cCAR-T) therapy, targeting B cells and plasma cells (33). This evidence concerns the gene CD19 and systemic lupus erythematosus.